Kimme L Hyrich

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely et al. · Annals of the Rheumatic Diseases · 2020 · 1.2K citations · Full text

Medicine, Infectious Diseases, Internal Medicine +16

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

William G Dixon, K. Watson, Mark Lunt et al. · Arthritis & Rheumatism · 2006 · 754 citations

Medicine, Infectious Diseases, Internal Medicine +15

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

William G Dixon, Kimme L Hyrich, Kath Watson et al. · Annals of the Rheumatic Diseases · 2009 · 710 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld, Martin Schäfer, Milena Gianfrancesco et al. · Annals of the Rheumatic Diseases · 2021 · 691 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +8